检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
出 处:《中医药学报》2006年第4期19-21,共3页Acta Chinese Medicine and Pharmacology
基 金:广东省中医药管理局资助(编号:102003)
摘 要:目的:研究脑梗塞模型大鼠海马、皮质凋亡相关基因bcl-2、bax及Bax、Bcl-2蛋白表达,探讨补肾活血丹对上述基因及蛋白表达的影响。方法:应用流式细胞仪测定模型小鼠细胞群中细胞凋亡基因bcl-2、bax的比例和Bax、Bcl-2蛋白含量。结果:补肾活血丹高、中、低3个剂量组和尼莫地平组均可见海马区及皮层区bcl-2免疫表达增强明显,而bax的免疫表达则与用药剂量及区域有关,其高剂量组可显著降低海马区和皮层区bax的表达,中剂量组和尼莫地平组仅降低皮层区bax的表达。模型组小鼠海马、皮质Bax、Bcl-2蛋白含量较正常对照组明显升高;Bcl-2蛋白水平在补肾活血丹高、中、低3个剂量组和尼莫地平组均有显著下调;Bax蛋白水平除补肾活血丹低剂量组外,其余组都有显著下调。结论:脑梗塞与神经细胞凋亡有关,补肾活血丹可能有一定的治疗作用。objective:To investigate the expression of gene bcl-2,bax and protein of Bcl-2,Bax which relates to apoptosis in hippocampi and cortex cell of rats with incomplete Cerebral Ischemia model,observe the effect of Bushen Huoxue Pill(BSHXP) on the expression of these genes.Method:Establish incomplete Cerberal Ischemia model of rats.The percent of apoptosis cell gene of bcl-2,bax and protein of Bcl-2,Bax in cell groups was measured and calculated with flow cytometry.Result:Three groups with high,moderate,low dosages of BSHXP and nimodipine group showed respectively immunity expression increase of bcl-2 at the area of hippocampi and cortex,but the immunity expression of bax related to the medicine dose and region.High dosage group could decrease the expression of Bax at the region of hippocampi and cortex,moderate group and nimodipine group only decreaced the expression of the bax at cortex.The protein content of Bax,Bcl-2 in hippocampi and cortex of the model group increased compared with the normal group.Bcl-2 protein levels of high,moderate,low groups with BSHXP and nimodipine group all decreased.Bax protein expression levels were all drop expect for the low dose group with BSHXP.Conclusion:Cerebral Ischemia disease has relation with nerve cell apoptosis,and BSHXP posses certain treating function.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15